Cargando…

Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease

Parkinson's disease (PD) is one of the most common chronic, progressive, and neurodegenerative diseases characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. As this disease is usually detected in the later stages, the cure is often delayed, ultimately le...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Xu, Yang, Yujia, Zhao, Zhengfan, Xu, Manyu, Zhang, Yuan, Sheng, Yingying, Tian, Junying, Xu, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385195/
https://www.ncbi.nlm.nih.gov/pubmed/34456846
http://dx.doi.org/10.3389/fneur.2021.680765
_version_ 1783742042905509888
author Yi, Xu
Yang, Yujia
Zhao, Zhengfan
Xu, Manyu
Zhang, Yuan
Sheng, Yingying
Tian, Junying
Xu, Zhiqiang
author_facet Yi, Xu
Yang, Yujia
Zhao, Zhengfan
Xu, Manyu
Zhang, Yuan
Sheng, Yingying
Tian, Junying
Xu, Zhiqiang
author_sort Yi, Xu
collection PubMed
description Parkinson's disease (PD) is one of the most common chronic, progressive, and neurodegenerative diseases characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. As this disease is usually detected in the later stages, the cure is often delayed, ultimately leading to disability due to the lack of early diagnostic techniques. Therefore, it is of great importance to identify reliable biomarkers with high sensitivity and specificity for the early diagnosis of PD. In this study, we aimed to investigate whether serum expressions of mature brain-derived neurotrophic factor (mBDNF) and proBDNF can serve as biomarkers for the diagnosis of PD at early stage. One hundred and fifty-six patients with limb tremor and/or bradykinesia meeting the inclusion criteria were assigned to either ex-PD group (PD cases) or ex-NPD group (non-PD cases) and then reassigned to either po-PD group (with PD) or po-NPD group (without PD) at 1-year follow-up based on the results of the rediagnoses as performed in accordance with MDS Parkinson's diagnostic criteria. To improve early diagnostic accuracy, grouping (PD group and non-PD group) at initial visit and follow-up was performed differently and independently. Serum mBDNF and proBDNF levels were measured by enzyme-linked immunosorbent assays. The results demonstrated that serum levels of mBDNF and mBDNF/proBDNF were significantly lower in the ex-PD group (19.73 ± 7.31 and 0.09 ± 0.05 ng/ml) as compared with the ex-NPD group (23.47 ± 8.21 and 0.15 ± 0.12 ng/ml) (p < 0.01 for both) and in the po-PD group (19.24 ± 7.20 and 0.09 ± 0.05 ng/ml) as compared with the po-NPD group (25.05 ± 7.67 and 0.16 ± 0.14 ng/ml) (p < 0.01 for both). However, a significantly higher serum level of proBDNF was noted in the ex-PD group (235.49 ± 60.75 ng/ml) as compared with the ex-NPD group (191.75 ± 66.12 ng/ml) (p < 0.01) and in the po-PD group (235.56 ± 60.80 ng/ml) as compared with the po-NPD group (188.42 ± 65.08 ng/ml) (p < 0.01). In conclusion, mBDNF/proBDNF can be used as biomarkers for early stage Parkinson's disease; in addition, mBDNF plus proBDNF has better diagnostic value than mBDNF alone in the diagnosis of PD.
format Online
Article
Text
id pubmed-8385195
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83851952021-08-26 Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease Yi, Xu Yang, Yujia Zhao, Zhengfan Xu, Manyu Zhang, Yuan Sheng, Yingying Tian, Junying Xu, Zhiqiang Front Neurol Neurology Parkinson's disease (PD) is one of the most common chronic, progressive, and neurodegenerative diseases characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. As this disease is usually detected in the later stages, the cure is often delayed, ultimately leading to disability due to the lack of early diagnostic techniques. Therefore, it is of great importance to identify reliable biomarkers with high sensitivity and specificity for the early diagnosis of PD. In this study, we aimed to investigate whether serum expressions of mature brain-derived neurotrophic factor (mBDNF) and proBDNF can serve as biomarkers for the diagnosis of PD at early stage. One hundred and fifty-six patients with limb tremor and/or bradykinesia meeting the inclusion criteria were assigned to either ex-PD group (PD cases) or ex-NPD group (non-PD cases) and then reassigned to either po-PD group (with PD) or po-NPD group (without PD) at 1-year follow-up based on the results of the rediagnoses as performed in accordance with MDS Parkinson's diagnostic criteria. To improve early diagnostic accuracy, grouping (PD group and non-PD group) at initial visit and follow-up was performed differently and independently. Serum mBDNF and proBDNF levels were measured by enzyme-linked immunosorbent assays. The results demonstrated that serum levels of mBDNF and mBDNF/proBDNF were significantly lower in the ex-PD group (19.73 ± 7.31 and 0.09 ± 0.05 ng/ml) as compared with the ex-NPD group (23.47 ± 8.21 and 0.15 ± 0.12 ng/ml) (p < 0.01 for both) and in the po-PD group (19.24 ± 7.20 and 0.09 ± 0.05 ng/ml) as compared with the po-NPD group (25.05 ± 7.67 and 0.16 ± 0.14 ng/ml) (p < 0.01 for both). However, a significantly higher serum level of proBDNF was noted in the ex-PD group (235.49 ± 60.75 ng/ml) as compared with the ex-NPD group (191.75 ± 66.12 ng/ml) (p < 0.01) and in the po-PD group (235.56 ± 60.80 ng/ml) as compared with the po-NPD group (188.42 ± 65.08 ng/ml) (p < 0.01). In conclusion, mBDNF/proBDNF can be used as biomarkers for early stage Parkinson's disease; in addition, mBDNF plus proBDNF has better diagnostic value than mBDNF alone in the diagnosis of PD. Frontiers Media S.A. 2021-08-11 /pmc/articles/PMC8385195/ /pubmed/34456846 http://dx.doi.org/10.3389/fneur.2021.680765 Text en Copyright © 2021 Yi, Yang, Zhao, Xu, Zhang, Sheng, Tian and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Yi, Xu
Yang, Yujia
Zhao, Zhengfan
Xu, Manyu
Zhang, Yuan
Sheng, Yingying
Tian, Junying
Xu, Zhiqiang
Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title_full Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title_fullStr Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title_full_unstemmed Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title_short Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease
title_sort serum mbdnf and probdnf expression levels as diagnosis clue for early stage parkinson's disease
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385195/
https://www.ncbi.nlm.nih.gov/pubmed/34456846
http://dx.doi.org/10.3389/fneur.2021.680765
work_keys_str_mv AT yixu serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT yangyujia serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT zhaozhengfan serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT xumanyu serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT zhangyuan serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT shengyingying serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT tianjunying serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease
AT xuzhiqiang serummbdnfandprobdnfexpressionlevelsasdiagnosisclueforearlystageparkinsonsdisease